Trial NCT02877082

View at ClinicalTrials.gov 
Org. Study IDs: IRB00082499
Secondary IDs: NCI-2016-01035 Winship3258-16

Last trial update was posted on 2018-04-30

MeSH Interventions

Antilymphocyte Serum Bortezomib Tacrolimus Thymoglobulin

MeSH Conditions

Graft vs Host Disease Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Lymphoma Lymphoma, Large B-Cell, Diffuse Lymphoma, Mantle-Cell Myelodysplastic Syndromes Myeloproliferative Disorders

Other Conditions

Acute Leukemia Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Diffuse Large B-Cell Lymphoma Follicular Lymphoma Graft Versus Host Disease Mantle Cell Lymphoma Marginal Zone Lymphoma Myelodysplastic Syndrome Myelofibrosis Myeloproliferative Neoplasm Small Lymphocytic Lymphoma

Stopping Reasons

N/A

Limitations And Caveats

After monitoring early toxicity and hyperacute severe acute graft versus host disease in 4/5 patients, it was decided to close this protocol.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID